- Home
- DMAC vs PHX Comparison
DMAC vs PHX Comparison
Compare DMAC & PHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- PHX
- Stock Information
- Founded
- DMAC 2000
- PHX 1926
- Country
- DMAC United States
- PHX United States
- Employees
- DMAC N/A
- PHX N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- PHX Oil & Gas Production
- Sector
- DMAC Health Care
- PHX Energy
- Exchange
- DMAC Nasdaq
- PHX Nasdaq
- Market Cap
- DMAC 178.0M
- PHX 163.8M
- IPO Year
- DMAC N/A
- PHX N/A
- Fundamental
- Price
- DMAC $3.63
- PHX $4.35
- Analyst Decision
- DMAC Strong Buy
- PHX Hold
- Analyst Count
- DMAC 2
- PHX 1
- Target Price
- DMAC $8.00
- PHX N/A
- AVG Volume (30 Days)
- DMAC 110.0K
- PHX 989.3K
- Earning Date
- DMAC 08-06-2025
- PHX 08-06-2025
- Dividend Yield
- DMAC N/A
- PHX 3.68%
- EPS Growth
- DMAC N/A
- PHX 71.86
- EPS
- DMAC N/A
- PHX 0.19
- Revenue
- DMAC N/A
- PHX $36,057,255.00
- Revenue This Year
- DMAC N/A
- PHX $30.25
- Revenue Next Year
- DMAC N/A
- PHX $4.76
- P/E Ratio
- DMAC N/A
- PHX $22.97
- Revenue Growth
- DMAC N/A
- PHX 16.49
- 52 Week Low
- DMAC $2.14
- PHX $3.09
- 52 Week High
- DMAC $6.82
- PHX $4.35
- Technical
- Relative Strength Index (RSI)
- DMAC 46.56
- PHX 65.13
- Support Level
- DMAC $4.02
- PHX $4.31
- Resistance Level
- DMAC $4.17
- PHX $3.97
- Average True Range (ATR)
- DMAC 0.25
- PHX 0.01
- MACD
- DMAC -0.04
- PHX -0.01
- Stochastic Oscillator
- DMAC 37.89
- PHX 100.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About PHX PHX Minerals Inc.
PHX Minerals Inc is an oil and natural gas mineral company that has employed a plan to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership. The company owns substantial mineral acreage, principally in Oklahoma, North Dakota, Texas, New Mexico, and Arkansas, but still maintains legacy interests in natural gas and oil properties that have retired operations. The revenues is derived from royalties granted from the production and sale of natural gas, oil and NGL, and the remaining portion of its revenues is derived from the production and sale of natural gas, oil and NGL on its working interests.